|
DDI2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62870000042226E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.51002999999594E-05 |
| Normal-vs-Stage2 |
1.581790E-03 |
| Normal-vs-Stage3 |
1.65180000011311E-07 |
| Normal-vs-Stage4 |
1.40629999978437E-07 |
| Stage1-vs-Stage2 |
7.896000E-01 |
| Stage1-vs-Stage3 |
2.486800E-01 |
| Stage1-vs-Stage4 |
6.861500E-02 |
| Stage2-vs-Stage3 |
2.892200E-01 |
| Stage2-vs-Stage4 |
1.473610E-01 |
| Stage3-vs-Stage4 |
5.196600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.07189999998258E-06 |
| Normal-vs-AfricanAmerican |
6.436400E-03 |
| Normal-vs-Asian |
1.31569999994863E-06 |
| Caucasian-vs-AfricanAmerican |
6.393600E-01 |
| Caucasian-vs-Asian |
2.221200E-01 |
| AfricanAmerican-vs-Asian |
1.805030E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.20129994840568E-09 |
| Normal-vs-Female |
4.41029999997955E-06 |
| Male-vs-Female |
1.459950E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.52399999999919E-05 |
| Normal-vs-Age(41-60Yrs) |
1.15990000004729E-06 |
| Normal-vs-Age(61-80Yrs) |
3.06600000055113E-07 |
| Normal-vs-Age(81-100Yrs) |
6.735800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.685600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.741000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.440000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.674800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.458600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.850800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.438200E-02 |
| Classical-VS-Follicular |
2.029800E-01 |
| Classical-VS-Other |
1.960870E-03 |
| Classical-VS-Normal |
1.57524999999659E-05 |
| Tall-VS-Follicular |
3.827800E-01 |
| Tall-VS-Other |
1.138370E-01 |
| Tall-VS-Normal |
2.74850000003823E-06 |
| Follicular-VS-Other |
8.999700E-03 |
| Follicular-VS-Normal |
2.00489999999665E-05 |
| Other-VS-Normal |
9.72219999950674E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.59440000002675E-06 |
| Normal-vs-N1 |
1.27969999996758E-06 |
| N0-vs-N1 |
2.641600E-01 |
|
|
